title: Management of thrombocytopenia in bone marrow failure: a review.
abstract: The clinical course of many neoplastic and primary bone marrow diseases will result in cytopenias secondary to bone marrow failure or infiltration. Acute and chronic leukemias, the myelodysplastic syndromes (MDS), aplastic anemia, breast and prostate cancer, as well as other hematologic and solid tumors, all may lead to chronic, severe cytopenias. Management of anemia and neutropenia are well described in the medical literature. Less well detailed are management approaches for patients with chronic thrombocytopenia, with or without active bleeding. Severe thrombocytopenia presents many difficult management choices for caregivers, patients and their families, especially near the end of life. The use of platelet transfusions in this patient population presents complex issues; platelets are logistically more difficult to transfuse than red cells and carry risks including acute febrile episodes, alloimmunization, and infection. In this review, we discuss the association of chronic thrombocytopenia to serious bleeding and the role of various prophylactic and therapeutic interventions available to palliative care and hospice providers. Specifically, this review examines the following issues: What is the morbidity and mortality from chronic thrombocytopenia in the setting of cancer or other bone marrow failure states? Is there a role for prophylactic platelet transfusions in the palliative care setting, and if so, with what frequency of monitoring, and at what transfusion threshold? What is the impact of alloimmunization and how can it be minimized? What treatments are available besides, or in addition to, platelet transfusions for acute bleeding episodes?
authors.affiliation: Specialists in Cancer Care, Saint Luke's Cancer Institute, 43212 Washington Drive, Kansas City, MO 64111, USA. msalacz@saint-lukes.org
authors.forename: Michael E
authors.initials: ME
authors.lastname: Salacz
authors.forename: Michael W
authors.initials: MW
authors.lastname: Lankiewicz
authors.forename: David E
authors.initials: DE
authors.lastname: Weissman
mesh_terms: D000933:Antifibrinolytic Agents / Q000627:therapeutic use; D001855:Bone Marrow Diseases / Q000150:complications*; D002908:Chronic Disease; D006801:Humans; D010166:Palliative Care; D010346:Patient Care Management; D017713:Platelet Transfusion; D013921:Thrombocytopenia / Q000209:etiology / Q000628:therapy*
chemical_list: D000933:Antifibrinolytic Agents